Healthy Clinical Trial
— ROBINOfficial title:
The Effect of Daily Consumption of a Probiotic Drink Containing Lactobacillus Casei Strain Shirota on the Small Intestinal Microbiota in Healthy Male Subjects as Measured by the IntelliCap Sampling Capsule System.
Currently, obtaining samples directly from the small bowel is difficult due to the highly invasive intubation methods used. Research on the effect of dietary probiotics on the gut microbiota is therefore largely dependent on measurement of the microbial composition in fecal samples. At best, the measurement in fecal samples reflects microbial composition of the large intestine. The microbial composition in the small intestine differs substantially from the composition in feces. In addition, many physiological processes that are modulated by dietary probiotics, such as immunoregulation, mainly occur in the small intestine. Therefore, it is vital to study the effects of dietary probiotics on the small intestinal microbiota, as well. Successful sampling of the small intestine has been demonstrated in animals and humans, using the IntelliCap® CR system. The main aim of the current study is to explore and compare the small intestinal microbiota profiles in healthy subjects before and after consumption of a probiotic drink containing Lactobacillus casei strain Shirota (LcS) (Yakult®).
Status | Recruiting |
Enrollment | 6 |
Est. completion date | February 28, 2018 |
Est. primary completion date | October 31, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 30 Years |
Eligibility |
Inclusion Criteria: 1. Male 2. Age 18-30yrs 3. BMI between 18,5-25 kg/m2 4. Healthy as assessed by the NIZO lifestyle and health questionnaire ("Verklaring leefgewoonten en gezondheid"). 5. Non-smoking 6. Regular bowel movement (defecation on average once a day, at least 4 times/week). 7. Signed informed consent 8. Access to internet 9. Access to freezer for storage of biological samples 10. Voluntary participation 11. Willing to accept disclosure of the financial benefit of participation in the study to the authorities concerned. 12. Willing to accept use of all encoded data, including publication, and the confidential use and storage of all data for the study for at least 15 years. 13. Willing to accept information-transfer concerning participation in the study, or information regarding health, like laboratory results, findings at anamnesis or physical examination and eventual adverse events to and from his general practitioner. 14. Willing to comply with study procedures. Exclusion Criteria: 1. Alcohol consumption > 15 units/week and > 3/day. 2. Allergic to dairy products (milk allergy or lactose intolerance). 3. Carrying a pacemaker or any other (implanted) medical electronic device. 4. Drug abuse. 5. Having diarrhea within two (2) months prior to the study start. 6. Heavy exercise or sports training > 10 hours/week. 7. History or presence of any clinically important disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study. 8. Mental status that is incompatible with the proper conduct of the study. 9. Participation in any scientific study with oral, intravenous or inhalatory administration of any substances during two (2) months before study start. 10. Presence of swallowing disorder or problems with gastro-intestinal transit. 11. Reported special diets such as vegetarian, vegan, or macrobiotic. 12. Scheduled for an MRI scan during the study period. 13. Unstable body weight (weight gain or loss >5kg in the past three (3) months). 14. Use of antibiotics during the six (6) months prior to study start. 15. Use of any prescribed or non-prescribed medication (other than paracetamol) during the three (3) weeks prior to study start. 16. Use of laxatives and probiotic, prebiotic and fiber supplements during the two (2) months prior to study start. 17. Personnel of research institute(s) involved in execution of the study, their partner and their first and second degree relatives 18. Not having a general practitioner 19. Not willing to have an X-ray if the capsule is not recovered from the feces. |
Country | Name | City | State |
---|---|---|---|
Netherlands | NIZO Food Research | Ede, Utrecht, |
Lead Sponsor | Collaborator |
---|---|
Yakult Honsha European Research Center, ESV | NIZO Food Research |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Biomarkers | Feasibility assessment of measuring potential biomarkers in the small intestine and feces | 7 days after consuming a probiotic drink containing LcS | |
Primary | Microbiota composition in the small intestine | Relative abundance of microbiota species (% of total) in the small intestine | 7 days after consuming a probiotic drink containing Lactobacillus casei strain Shirota (LcS) | |
Secondary | Microbiota composition in feces | Relative abundance of microbiota species (% of total ) in feces | 7 days after consuming a probiotic drink containing LcS | |
Secondary | LcS recovery | LcS recovery in the small intestine and feces | 7 days after consuming a probiotic drink containing LcS | |
Secondary | Stool habits | Effect of LcS on stool frequency, stool consistency and gastrointestinal symptoms | 7 days after consuming a probiotic drink containing LcS |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |